Advertisement

The Design, Synthesis and Structure–Activity Relationship of Mixed Serotonin, Norepinephrine and Dopamine Uptake Inhibitors

  • Zhengming Chen
  • Ji Yang
  • Phil Skolnick
Chapter
Part of the Topics in Medicinal Chemistry book series (TMC, volume 4)

Abstract

The evolution of antidepressants over the past four decades has involved the replacement of drugswith a multiplicity of effects (e.g., TCAs) by those with selective actions (i.e., SSRIs). This strategywas employed to reduce the adverse effects of TCAs, largely by eliminating interactions with certain neurotransmittersor receptors. Although these more selective compounds may be better tolerated by patients, selective drugs,specifically SSRIs, are not superior to older drugs in treating depressed patients as measured by responseand remission rates. It may be an advantage to increase synaptic levels of both serotonin and norepinephrine,as in the case of dual uptake inhibitors like duloxetine and venlafaxine. An important recent developmenthas been the emergence of the triple-uptake inhibitors (TUIs/SNDRIs), which inhibit the uptake of the threeneurotransmitters most closely linked to depression: serotonin, norepinephrine, and dopamine. Preclinicalstudies and clinical trials indicate that a drug inhibiting the reuptake of all three of these neurotransmitterscould produce more rapid onset of action and greater efficacy than traditional antidepressants. This reviewwill detail the medicinal chemistry involved in the design, synthesis and discovery of mixed serotonin,norepinephrine and dopamine transporter uptake inhibitors.

Design Monoamine SNDRI Synthesis and SAR Triple-uptake inhibitor  

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kuhn R (1958) Am J Psychiatry 115:459 Google Scholar
  2. 2.
    Glowinski J, Axelrod J (1964) Nature 204:1318 CrossRefGoogle Scholar
  3. 3.
    Schildkraut JJ (1965) Am J Psychiatry 122:509 Google Scholar
  4. 4.
    Carlsson A, Fuxe K, Ungerstedt U (1968) J Pharm Pharmacol 20:150 CrossRefGoogle Scholar
  5. 5.
    Blakely RD, DeFelice LJ, Galli A (2005) Physiology 20:225 CrossRefGoogle Scholar
  6. 6.
    Berten O, Nestler EJ (2006) Nat Rev Neurosci 7:137 CrossRefGoogle Scholar
  7. 7.
    Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S (2005) NeuroRx 2:590 CrossRefGoogle Scholar
  8. 8.
    Schubert-Zsilavecz M, Stark H (2004) Pharm Unserer Zeit 33:282 CrossRefGoogle Scholar
  9. 9.
    Leonard BE (ed) (2001) Antidepressants. Birkhaeuser Verlag, Basel Google Scholar
  10. 10.
    Roth BL, Kroeze WK, Patel S, Lopez E (2000) Neuroscientist 6:252 CrossRefGoogle Scholar
  11. 11.
    Carlsson A (1987) Ann Rev Neurosci 10:19 CrossRefGoogle Scholar
  12. 12.
    Lemberger L, Rowe H, Carmichael R, Oldham S, Horng JS, Bymaster FP, Wong DT (1978) Science 199:436 CrossRefGoogle Scholar
  13. 13.
    Wong DT, Perry KW, Bymaster FP (2005) Nat Rev Drug Discov 4:764 Google Scholar
  14. 14.
    Ban TA (2001) J Neural Transm 108:707 CrossRefGoogle Scholar
  15. 15.
    Bymaster FP, McNamara RK, Tran PV (2003) Expert Opin Investig Drugs 12:531 CrossRefGoogle Scholar
  16. 16.
    Holtzheimer PE III, Nemeroff CB (2006) Expert Opin Pharmacother 7:2323 CrossRefGoogle Scholar
  17. 17.
    Danish University Antidepressant Group (1986) Psychopharmacology 90:131 Google Scholar
  18. 18.
    Danish University Antidepressant Group (1990) J Affective Disord 18:289 CrossRefGoogle Scholar
  19. 19.
    Wong DT, Bymaster FP (2002) Prog Drug Res 58:169 CrossRefGoogle Scholar
  20. 20.
    Stahl SM, Grady MM, Moret C, Briley M (2005) CNS Spectr 10:732 Google Scholar
  21. 21.
    Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996) Int Clin Psychopharmacol 11(4):41 CrossRefGoogle Scholar
  22. 22.
    Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ (2004) Biol Psych 55:320 CrossRefGoogle Scholar
  23. 23.
    Eckert L, Lancon C (2006) BMC Psychiatry 6:30 CrossRefGoogle Scholar
  24. 24.
    Richelson E (2003) J Clin Psychiatry 64(13):5 Google Scholar
  25. 25.
    Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ (1997) Br J Pharmacol 121:1613 CrossRefGoogle Scholar
  26. 26.
    Papakostas GI (2006) Eur Neuropsychopharmacol 16:391 CrossRefGoogle Scholar
  27. 27.
    Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (2006) N Engl J Med 354:1243 CrossRefGoogle Scholar
  28. 28.
    Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A (2006) CNS Drug Rev 12:123 CrossRefGoogle Scholar
  29. 29.
    Beer B, Stark J, Krieter P, Czobor P, Beer G, Lippa A, Skolnick P (2004) J Clin Pharmacol 44:1360 CrossRefGoogle Scholar
  30. 30.
    Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS (2003) Eur J Pharmacol 461:99 CrossRefGoogle Scholar
  31. 31.
    Epstein JW, Brabander HJ, Fanshawe WJ, Hofmann CM, McKenzie TC, Safir SR, Osterberg AC, Cosulich DB, Lovell FM (1981) J Med Chem 24:481 CrossRefGoogle Scholar
  32. 32.
    Skolnick P, Basile AS (2006) Drug Discov Today 3:489 CrossRefGoogle Scholar
  33. 33.
    Skolnick P, Basile AS (2007) CNS Neurol Disord Drug Targets 6:141 CrossRefGoogle Scholar
  34. 34.
    Skolnick P, Popik P, Janowsky A, Beer, Lippa AS (2003) Life Sci 73:3175 CrossRefGoogle Scholar
  35. 35.
    Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS (2006) Cell Mol Neurobiol 26:857 CrossRefGoogle Scholar
  36. 36.
    McMillen BA, Shank JE, Williams HL, Basile AS (2007) Alcohol Clin Exp Res 31:in press Google Scholar
  37. 37.
    Skolnick P, Basile A, Chen Z (2006) Int Patent Appl WO 2006096810 Google Scholar
  38. 38.
    Carlier PR, Lo MMC, Lo PCK, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA (1998) Bioorg Med Chem Lett 8:487 CrossRefGoogle Scholar
  39. 39.
    Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, Richelson E (2007) Eur J Pharmacol 555:30 CrossRefGoogle Scholar
  40. 40.
    Axford L, Boot JR, Hotten TM, Keenan M, Martin FM, Milutinovic S, Moore NA, O'Neill MF, Pullar IA, Tupper DE, Van Belle KR, Vivien V (2003) Bioorg Med Chem Lett 13:3277 CrossRefGoogle Scholar
  41. 41.
    Cases M, Masters JJ, Haughton L, Campbell G, Mann T, Rudyk H, Walter MW, Timms G, Gilmore J, Dobson DR, White C, Boot JR, Findlay JD, Hayhurst L, Kluge AH (2005) 230th ACS Meeting. Washington, DC Google Scholar
  42. 42.
    Moldt P, Wätjen F, Scheel-Krüger J (1998) US Patent 5736556 Google Scholar
  43. 43.
    Scheel-Krüger J, Moldt P, Wätjen F (2001) US Patent 6288079 Google Scholar
  44. 44.
    Scheel-Krüger J, Moldt P, Wätjen F (2002) US Patent 6395748 Google Scholar
  45. 45.
    NeuroSearch (2003) Jul 3 press release Google Scholar
  46. 46.
    NeuroSearch (1999) Ann Rep Google Scholar
  47. 47.
    NeuroSearch (2002) Ann Rep Google Scholar
  48. 48.
    JP Morgan 22nd Ann Healthcare Conference (2004) San Francisco, CA Google Scholar
  49. 49.
    Sepracor (2004) 3rd Quarter Release Google Scholar
  50. 50.
    Sepracor (2005) Apr 25 press releases Google Scholar
  51. 51.
    Sepracor (2005) Oct 19 press releases Google Scholar
  52. 52.
    AMRI (2005) Oct 24 press release Google Scholar
  53. 53.
    AMRI Drug Discovery Symposium (2006) Albany, NY Google Scholar
  54. 54.
    Zhou J, He R, Johnson KM, Ye Y, Kozikowski AP (2004) J Med Chem 47:5821 CrossRefGoogle Scholar
  55. 55.
    Zhou J, Johnson KM, Giberson KM, McGonigle P, Caldarone BJ, Kozikowski AP (2006) 232nd ACS national meeting. San Francisco, CA Google Scholar
  56. 56.
    Zhang S, Zhen J, Reith MEA, Dutta AK (2005) J Med Chem 48:4962 CrossRefGoogle Scholar
  57. 57.
    Zhang S, Fernandez F, Hazeldine S, Deschamps J, Zhen J, Reith MEA, Dutta AK (2006) J Med Chem 49:4239 CrossRefGoogle Scholar
  58. 58.
    Yu H, Kim IJ, Folk JE, Tian X, Rothman RB, Baumann MH, Dersch CM, Flippen-Anderson JL, Parrish D, Jacobson AE, Rice KC (2004) J Med Chem 47:2624 CrossRefGoogle Scholar
  59. 59.
    Enyedy IJ, Zaman WA, Sakamuri S, Kozikowski AP, Johnsonc KM, Wang S (2001) Bioorg Med Chem Lett 11:1113 CrossRefGoogle Scholar
  60. 60.
    Houlihan WJ, Kelly L, Pankuch J, Koletar J, Brand L, Janowsky A, Kopajtic TA (2002) J Med Chem 45:4097 CrossRefGoogle Scholar
  61. 61.
    Houlihan WJ, Ahmad UF, Koletar J, Kelly L, Brand L, Kopajtic TA (2002) J Med Chem 45:4110 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  1. 1.DOV Pharmaceutical, Inc.SomersetUSA

Personalised recommendations